TY - JOUR
T1 - Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
AU - Carter, Jeanne
AU - Huang, Helen Q.
AU - Monk, Bradley J.
AU - Kim, Yong Beom
AU - Kim, Moon Hong
AU - Stuckey, Ashley
AU - Vicus, Danielle L.
AU - Holman, Laura L.
AU - Fleury, Aimee C.
AU - Pearson, J. Matthew
AU - Thawani, Nitika
AU - Shahin, Mark
AU - Lea, Jayanthi
AU - Robertson, Sharon E.
AU - Warshal, David
AU - Backes, Floor J.
AU - Feltmate, Colleen
AU - Wilkinson-Ryan, Ivy
AU - Covens, Allan
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/4
Y1 - 2025/4
N2 - Objective: To examine patient outcomes before and after cone biopsy (CB) or simple hysterectomy (SH) and pelvic lymph node dissection (PLND) for bladder, bowel, and sexual function, quality of life (QOL), cancer worry, reproductive concerns, and lymphedema. Methods: We stratified women with stage IA1 (lymphovascular space invasion–positive) and IA2-IB1 (≤2 cm) cervical carcinoma by fertility preservation (CB) or none (SH) with PLND. All patients completed study questionnaires at baseline (preoperatively) and postoperatively at 4–6 weeks and 6-, 12-, 18-, and 24-months, consisting of: Functional Assessment Cancer Therapy - Cervical Cancer (FACT-Cx); Female Sexual Functioning Index (FSFI), and 2 Patient-Reported Outcomes Measurement Information System (PROMIS) items; Gynecologic Cancer Lymphedema Questionnaire (GCLQ); Impact of Events Scale (IES); and Reproductive Concerns Scale (RCS). Results: We enrolled 224 patients from 10/12 to 10/21, with 72 choosing CB and 152 SH. A total of 169 patients (54 CB; 115 SH) were eligible for QOL analysis and completed baseline assessment with at least one follow-up assessment. Postoperatively in both groups, bladder and bowel function slightly decreased but recovered over time, sexual function declined at 6 weeks but improved over time, QOL increased, and cancer worry decreased. As per the GCLQ, 12 patients reported a diagnosis of lymphedema with a GCLQ score change ≥4 (6 CB; 6 SH). Conclusions: Nonradical surgery for early-stage cervical cancer is associated with excellent QOL and small decreases in physical function (bladder, bowel, sexual) that quickly improve postoperatively to baseline or above. Lymphedema rates were low but present in both groups.
AB - Objective: To examine patient outcomes before and after cone biopsy (CB) or simple hysterectomy (SH) and pelvic lymph node dissection (PLND) for bladder, bowel, and sexual function, quality of life (QOL), cancer worry, reproductive concerns, and lymphedema. Methods: We stratified women with stage IA1 (lymphovascular space invasion–positive) and IA2-IB1 (≤2 cm) cervical carcinoma by fertility preservation (CB) or none (SH) with PLND. All patients completed study questionnaires at baseline (preoperatively) and postoperatively at 4–6 weeks and 6-, 12-, 18-, and 24-months, consisting of: Functional Assessment Cancer Therapy - Cervical Cancer (FACT-Cx); Female Sexual Functioning Index (FSFI), and 2 Patient-Reported Outcomes Measurement Information System (PROMIS) items; Gynecologic Cancer Lymphedema Questionnaire (GCLQ); Impact of Events Scale (IES); and Reproductive Concerns Scale (RCS). Results: We enrolled 224 patients from 10/12 to 10/21, with 72 choosing CB and 152 SH. A total of 169 patients (54 CB; 115 SH) were eligible for QOL analysis and completed baseline assessment with at least one follow-up assessment. Postoperatively in both groups, bladder and bowel function slightly decreased but recovered over time, sexual function declined at 6 weeks but improved over time, QOL increased, and cancer worry decreased. As per the GCLQ, 12 patients reported a diagnosis of lymphedema with a GCLQ score change ≥4 (6 CB; 6 SH). Conclusions: Nonradical surgery for early-stage cervical cancer is associated with excellent QOL and small decreases in physical function (bladder, bowel, sexual) that quickly improve postoperatively to baseline or above. Lymphedema rates were low but present in both groups.
UR - https://www.scopus.com/pages/publications/86000277543
UR - https://www.scopus.com/pages/publications/86000277543#tab=citedBy
U2 - 10.1016/j.ygyno.2025.02.023
DO - 10.1016/j.ygyno.2025.02.023
M3 - Article
C2 - 40058184
AN - SCOPUS:86000277543
SN - 0090-8258
VL - 195
SP - 50
EP - 58
JO - Gynecologic Oncology
JF - Gynecologic Oncology
ER -